Showing results (81-90 of 148) with videos related to
Sort By:
Pageof 15
International Journal of Cardiology|October 15, 2016
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle EastNasreen Al Sayed, Khalid Al Waili, Fatheya Alawadi, et al.Atherosclerosis|July 18, 2002
Regulation of small dense LDL concentration in Korean and Scottish men and womenHong Keun Cho, Gilja Shin, Sung Kee Ryu, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|February 18, 2011
The incidence and risk factors for new onset atrial fibrillation in the PROSPER studyPeter W Macfarlane, Heather Murray, Naveed Sattar, et al.AIDS (London, England)|February 18, 2015
Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysisTaraz Samandari, Tefera B Agizew, Samba Nyirenda, et al.Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.Diabetes|October 27, 2004
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention studyNaveed Sattar, Olga Scherbakova, Ian Ford, et al.Journal of Lipid Research|July 7, 2009
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trialNirupa R Matthan, Nancy Resteghini, Michele Robertson, et al.Atherosclerosis|March 30, 2007
Effect of pravastatin on the development of diabetes and adiponectin productionToshiyuki Takagi, Morihiro Matsuda, Manabu Abe, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 19, 2008
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets studyDouglas C A Taylor, Ankur Pandya, David Thompson, et al.Pageof 15